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Introduction
Phosphorous oxoanions are present in pharmaceutical for-
mulations due to two sources: as active ingredients (ortho-
phosphate and hypophosphite) or as salt forming agents,
counter-ions of several organic active ingredients. In the first
case, orthophosphate is used in hypercalcemia and as urinary
acidificant. Hypophosphites, apart from its former use in the
treatment of tuberculosis, are used as anabolyzing agents, by
favouring the biosynthesis of proteins. In the second case,
there are several therapeutic salts involving phosphate as
counter-ion such as, for instance, codeine phosphate, pyri-
doxal phosphate or dexamethasone phosphate.
Phosphonoformate is a potent antivirus substance which
produces, as degradation products phosphite and phosphate;
it requires suitable analytical methods for its monitoring in
biological fluids [1].
Phosphorous oxoanions, when present as minor or trace
level, are currently determined spectrophotometrically,
preferably as molybdenum blue or using the phospho-
vanadomolybdate method [2]. Phosphate is directly deter-
mined. Hypophosphite and phosphite are oxidized to phos-
phate prior their quantitation [2]. This standard procedure is
tiresome compared with some recent procedures based on
ion chromatography (IC). Tanaka et al. [3] and Biesaga and
Trojanowicz [4] determined phosphorous oxoanions in plat-
ing solutions using the suppressed IC. Ryder [5] described
the separation of phosphorous oxoanions by using single-
column IC with conductivity detector employing succinic
acid (pH 3) as eluent. Hatton and Pickering [6] analized
phosphorous oxoanions and other inorganic anions using p-
hydroxybenzoic acid or p-aminobenzoic acid as suitable elu-
ents and refractive index detection. Schmuckler et al. [7]
proposed the use of gluconate-borate eluent for anion
chromatography, which is actually, the eluent most widely
used in non-suppressed or single column IC. Moreover,
Waters Corporation commercializes a borate-gluconate type
eluent for these purposes [8]. Ruiz et al. [9] used this elu-
ent to determine inorganic water-soluble phosphate in veg-
tables. Bello and González [10] have been adapted the
orate-gluconate procedure to determine phosphate in cola
beverages.
The aim of the present paper is the study of separation
and quantitation of hypophosphite, phosphite and phosphate
by non suppressed IC with conductometric detection and its
application to the determination of phosphorous oxoanions
in drug formulations. The proposed procedure is fast, feasi-
ble, accurate and favourably compares with the time-con-
suming spectrophotometric methods. However, the price of
the apparatus is much higher. Anyway, taking into account
that standard HPLC systems are today available in the
majority of research labs, the only extra requirements to





A Waters 501 HPLC pump was used together with a Waters
IC-Pak A HR packed with polymetacrylate resin with a qua-
ternary ammonium functional group (6 µm particle size and
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exchange capacity of 30 ± 3 µeq mL–1) fitted with a Waters
Guard-Pak precolumn. Samples were injected by using a
Rheodyne type injector with a 100 µL loop. Detection was
done from a Waters 341 Conductivity detector. Peak evalu-
ations were done with an Hewlett Packard HP3395 
integrator.
Chromatographic conditions
Eluent preparation: Prepare the concentrate solution A by
dissolving 16 g of sodium gluconate, 18 g of boric acid and
25 g of sodium tetraborate in a mixture 25:75 v/v of 
glycerol:water to 1 L.
The working eluent is prepared by mixing 12 mL of
concentrate solution A, 20 mL of n-butanol, 120 mL of
acetonitrile and water up to 1 litre (pH 8.4). This eluent was
degassed and micro-filtered (0.2 µm) before use. Its conduc-
tivity was of about 180 µS (% Full Scale).
The flow rate was 1 mL min–1. The detector operates at
a Base range of 200 µS and the integrator was used with an
attenuation of 128.
Reagents
Potassium permanganate (Merck), Potassium phosphate
(Merck), phosphorous acid (Aldrich), sodium hypophosphite
monohydrate (Fluka), boric acid (Merck), sodium gluconate
(Fluka), sodium tetraborate decahydrate (Riedel), glycerol,
n-butanol and acetonitrile (Merck) were of analytical reagent
grade or better. Milli-Q treated water was used throughout.
Stock solutions of phosphate, phosphite and hypophos-
phite of 1000 mg L–1 were prepared and standardized if 
necessary.
For the sample mineralization, concentrated nitric acid
and 30% hydrogen peroxide (Merck) were utilized.
Samples
Phosphate was determined in three antitusive formulations
based on codeine phosphate (INISTON ANTITUSIVO®‚
(Gayoso Wellcome), CODEISAN®‚ (Abelló) and FIORI-
NAL CODEINA®‚ (Sandoz Pharma)). Hypophosphite was
determined in three nutritional restoratives (CALCIO-
GEVE®‚ (Bama-Geve), OSVICAL®‚ and OSVICAL-
LISINA®‚ (Alter)). The composition of each formulation is
given in the Appendix.
Procedures
Sample treatments
Samples containing phosphate were alkalized (pH 8.5–9),
diluted and passed through a Waters C18 SEP-Pak Plus car-
tridge (short body) before injection. Samples containing
hypophosphite were digested with concentrated nitric acid
and hydrogen peroxide in a sand bath near to dryness.
Diluted portions were directly injected.
Calibration features 
The chromatographic signal used in calibrations was the
height peak ratio (with respect to the internal standard)
according their reliability, better than peak area ratio.
A series (n = 10) of standard solutions (four replicates)
of phosphorous oxoanions were prepared and measured.
Data about the calibration graphs are collected in table I.
Hypophosphite coelutes with the injection peak and a
derivatization prior injection is required. So, standard solu-
tions of hypophosphite were oxidized into phosphate with
permanganate 0.5 M in acidic medium [2]. The excess of
permanganate was removed with 3% hydrogen peroxide.
The application of Student’s t-test shows that the inter-
cepts are insignificant and accordingly, the straight lines
passe through the origin.
Results and discussion
The separation of hypophosphite, phosphite and phosphate,
in the proposed mobile phase shows good resolution 
(Fig. 1). The species involved in the separation at the pH of
the mobile phase were: H2PO2–, HPO–23 and HPO42–. One
characteristic of the non-suppressed IC with conductivity
detection is the appearance of an injection peak; this is due
to the displacement of the eluent ions by the injected ions
[11]. Unfortunately, the peak corresponding to hypophos-
phite is very close to the injection peak, as can be seen in
figure 1, and so, it coelutes with it. Accordingly, hypo-
phosphite cannot be accurately quantitated directly from the
chromatogram. It is more advisable to perform a derivatiza-
tion into phosphate prior injection. If the sample contains
both phosphate and hypophosphite, two injections are
needed: with and without derivatization.
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Table I. Calibration data.
Analyte Regression parameters LCRa rb LODc
Phosphate y = (0.012 ± 0.006) + (0.098 ± 0.001)x 0.5–10 0.9994 0.2 
Phosphite y = (0.022 ± 0.006) + (0.176 ± 0.001)x 0.5–8 0.9990 0.1 
Hypophosphited y = (0.01 ± 0.01) + (0.103 ± 0.002)x 0.5–10 0.9986 0.3 
a Linear concentration range (mg L–1); b Correlation coefficient; c Detection limit (mg L–1); d After derivatization (see text).
Tanking into account that (apart from its appearance as a
metabolite of phosphonoformate) phosphite is scarcely
found in pharmaceutical formulations, the proposed proce-
dure was applied only to samples containing phosphate or
hypophosphite. The results obtained as percentage of the
content of active ingredient claimed in the label for both the
proposed method and a spectrophotometric method [2] are
presented in table II. As can be observed, good agreement
were found between both procedures. This was statistically
proved according to the paired t-test [12] and also by con-
sidering the label claimed for analyzed samples, within the
confidence limits accepted by pharmacopoeias.
Conclusions
The proposed IC method for determining phosphorous
oxoanions is faster and easier than the conventional spec-
trophotometric procedures; however, investment is higher.
The necessity of hypophosphite derivatization is not a 
drawback because in mixtures, the spectrophotometric pro-
cedure requires the conversion of any phosphorous oxoanion
into phosphate. The proposed IC method applied to several
pharmaceutical formulations gives good results.
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Appendix
Composition of the analyzed samples
CODEISAN® (contents for 15 mL of syrup)
Codeine phosphate hemihydrate 19 mg
Ephedrine hydrochloride 30 mg
Sodium Benzoate 150 mg
Fluid extract of primrose 100 mg
Flavoured syrup, excipient up to 15 mL
INISTON ANTITUSIVO® (contents for 5 mL of syrup)
Codeine phosphate hemihydrate 10.60 mg
Pseudoephedrine hydrochloride 28.25 mg
Tripolidine hydrochloride 1.40 mg
Sucrose (excipient) 3.5 g
FORINAL CODEINA® (content for one capsule)
Codeine phosphate hemihydrate 14.67 mg
Caffeine anhydrous 40 mg
Acetaminophen 300 mg
Acetylsalicylic acid 200 mg
CALCIO GEVE® (contents for one effervescent tablet)
Calcium hypophosphite 100 mg
Calcium levulinlactogluconate 500 mg
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Fig. 1. Separation of phosphorous oxoanions by the described pro-
cedure. Injection of 100 µl containing 5 mg L–1 of each oxoanion.
Table II. Percentage of the label claimed for the analysed samples obtained from the proposed method and from spectrophotometric 
methods (see text).
SAMPLE HYPOPHOSPHITE PHOSPHATE
Proposed method Spectrophotometric method Proposed method Spectrophotometric method 
Codeisán® — — 97.5% 98.2%
Inistón Antitusivo® — — 96.2% 97.1% 
Fiorinal Codeina® — — 98.4% 98.1% 
Calcio Geve® 99.5% 99.3% — — 
Osvical® 101.7% 100.9 % — — 
Osvical Lisina® 98.8% 99.3 % — — 
Calcium heptagluconate 500 mg
Vitamin C 1000 mg
Vitamin D3 3000 IU
Sodium benzosulphimide 7 mg
OSVICAL® (contents for one effervescent tablet)
Calcium hypophosphite 686 mg
Calcium levulinate-carbonate 846 mg
Vitamin C 500 mg
Cholecalciferol 100 IU
Saccharine 60 mg
OSVICAL LISINA® (contents for one tablet)
Calcium hypophosphite 300.00 mg
Calcium ascorbate 560.00 mg
Calcium pantoneate 5.00 mg
Carnitine hydrochloride 200.00 mg
Cobamamide 0.15 mg
Ergocalciferol 12.50 µg
Lisine hydrochloride 250.00 mg
Calcium adipate 50.00 mg
Calcium carbonate 100.00 mg
Calcium citrate 1315.00 mg.
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